ATI RN
Final Exam Pathophysiology
1. A patient is being educated about the use of raloxifene (Evista) for osteoporosis. What is the primary therapeutic action of this medication?
- A. It stimulates the formation of new bone.
- B. It decreases bone resorption and increases bone density.
- C. It increases the excretion of calcium through the kidneys.
- D. It increases calcium absorption in the intestines.
Correct answer: B
Rationale: The correct answer is B: 'It decreases bone resorption and increases bone density.' Raloxifene, a selective estrogen receptor modulator (SERM), works by decreasing bone resorption, which is the breakdown of bone, and increasing bone density. This action helps in preventing bone loss and maintaining bone strength. Choice A is incorrect because raloxifene does not stimulate the formation of new bone but rather prevents its breakdown. Choice C is incorrect as raloxifene does not increase the excretion of calcium but rather helps in maintaining calcium levels in the bones. Choice D is also incorrect as raloxifene does not directly increase calcium absorption in the intestines.
2. A patient with a history of osteoporosis is prescribed alendronate (Fosamax). What specific instructions should the nurse provide to ensure the effectiveness of the medication?
- A. Take the medication with a full glass of water and remain upright for at least 30 minutes to prevent esophageal irritation and ensure proper absorption.
- B. Take the medication with milk to enhance calcium absorption.
- C. Take the medication at bedtime to ensure absorption during sleep.
- D. Take the medication with food to prevent nausea.
Correct answer: A
Rationale: The correct answer is A. Alendronate should be taken with a full glass of water, and patients should remain upright for at least 30 minutes to prevent esophageal irritation and ensure proper absorption. This positioning helps reduce the risk of esophageal irritation and ensures adequate drug absorption. Choice B is incorrect because alendronate should be taken with water, not milk. Choice C is incorrect as there is no specific advantage to taking alendronate at bedtime. Choice D is incorrect because taking alendronate with food may interfere with its absorption.
3. A woman suffers from amenorrhea. Which of the following medications will most likely be prescribed?
- A. Testosterone
- B. Follicle-stimulating hormone
- C. Estrogen
- D. Lactate
Correct answer: C
Rationale: Estrogen is the correct answer. Amenorrhea, the absence of menstruation, is often due to hormonal imbalances. Estrogen plays a crucial role in regulating the menstrual cycle. Prescribing estrogen can help address these hormonal imbalances and restore menstrual cycles. Testosterone (Choice A) is not typically prescribed for amenorrhea in women as it can further disrupt hormonal balance. Follicle-stimulating hormone (Choice B) is involved in stimulating ovulation and follicle development, not the primary treatment for amenorrhea. Lactate (Choice D) is not a medication used to treat amenorrhea.
4. A patient is prescribed zanamivir (Relenza) to treat influenza B. The patient has a history of asthma. For which of the following symptoms should the nurse assess?
- A. Bradycardia
- B. Pneumonia
- C. Bronchospasm
- D. Pulmonary embolism
Correct answer: C
Rationale: The correct answer is C: Bronchospasm. Zanamivir (Relenza) is an inhaled medication used to treat influenza by reducing the severity and duration of symptoms. Patients with a history of asthma are at risk of bronchospasm as a potential side effect of zanamivir. Assessing for bronchospasm is crucial in this case to ensure the patient's safety and well-being. Choices A, B, and D are incorrect. Bradycardia, pneumonia, and pulmonary embolism are not commonly associated with zanamivir use in the treatment of influenza B, especially in a patient with a history of asthma.
5. An 8-year-old boy has been diagnosed with a sex hormone deficiency and has begun a course of treatment with testosterone. What change in the boy's health status would necessitate a stop to the course of treatment?
- A. Excessive growth in height
- B. Signs of puberty
- C. Recurrent urinary tract infections
- D. Increased blood pressure
Correct answer: B
Rationale: In an 8-year-old boy with a sex hormone deficiency being treated with testosterone, the appearance of signs of puberty would necessitate stopping the treatment. Testosterone therapy in this case aims to supplement the deficient sex hormones but should not trigger premature puberty. Excessive growth in height (choice A) is not a typical reason to stop testosterone therapy. Recurrent urinary tract infections (choice C) and increased blood pressure (choice D) are not directly related to testosterone therapy in this context.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access